IMVT · Immunovant, Inc.
$39.05
-0.48 (-1.21%)
At close · Jul 22
Market Cap
$8.02B
Shares
205.31M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$505.61M
-22.2%
FY2026
Diluted EPS
-$2.77
-1.5%
FY2026
Operating Cash Flow
-$407.31M
-8.4%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | — | $24.95M | $7.58M | $0 | — | — | — | |
| $456.66M | $360.92M | $212.93M | $160.26M | $101.81M | $68.6M | $47.93M | $25.73M | |
| $76.24M | $77.24M | $57.28M | $48.02M | $54.23M | $39.51M | $18.15M | $2.69M | |
| $532.9M | $438.15M | $282.71M | $218.28M | $156.03M | $108.12M | $66.08M | $28.43M | |
| — | — | — | — | — | $0 | $625K | — | |
| $2.18M | $471K | -$1.01M | -$253K | -$781K | $328K | $412K | -$155K | |
| -$505.39M | -$412.95M | -$258.77M | -$210.95M | -$156.81M | -$107.79M | -$66.29M | -$28.58M | |
| $215K | $891K | $567K | $9000 | -$84K | -$358K | $97K | $19K | |
| -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M | -$107.43M | -$66.39M | -$28.6M | |
| -$506.34M | -$414.29M | -$258.28M | -$210.51M | -$156.03M | -$107.71M | -$66.75M | -$28.41M | |
| USD/shares | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 | -$1.22 | — | — |
| USD/shares | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 | -$1.22 | — | — |
| shares | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M | 43.2M | 22.17M |
| shares | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M | 43.2M | 22.17M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.58×
EV/EBIT
—
Biotechnology median 26.69×
P/E (TTM)
—
Biotechnology median 7.06×
Key facts
CIK
1764013
CUSIP
45258J102
13F (30d)
16 filings
16 filers
Visit website
Investor relations